Resona Asset Management Co. Ltd. Trims Position in Alnylam Pharmaceuticals, Inc. $ALNY

Resona Asset Management Co. Ltd. trimmed its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 5.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 41,497 shares of the biopharmaceutical company’s stock after selling 2,203 shares during the period. Resona Asset Management Co. Ltd.’s holdings in Alnylam Pharmaceuticals were worth $18,869,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Root Financial Partners LLC purchased a new stake in Alnylam Pharmaceuticals in the 3rd quarter worth $25,000. Salomon & Ludwin LLC purchased a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at about $27,000. Atlantic Union Bankshares Corp bought a new position in shares of Alnylam Pharmaceuticals in the second quarter worth about $30,000. ORG Partners LLC grew its position in shares of Alnylam Pharmaceuticals by 70.2% during the third quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 33 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth about $37,000. Institutional investors own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ALNY. Leerink Partners lowered their price target on Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating on the stock in a report on Monday, December 15th. HC Wainwright set a $570.00 target price on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, November 4th. Royal Bank Of Canada dropped their target price on shares of Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating for the company in a research report on Tuesday, January 20th. JPMorgan Chase & Co. cut their target price on shares of Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating for the company in a research note on Monday, October 13th. Finally, Bank of America decreased their price target on shares of Alnylam Pharmaceuticals from $530.00 to $529.00 and set a “buy” rating on the stock in a research note on Monday, January 12th. Twenty-two analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $485.21.

Alnylam Pharmaceuticals Trading Down 3.2%

Shares of ALNY opened at $357.98 on Friday. The stock has a market capitalization of $47.29 billion, a PE ratio of 1,491.58 and a beta of 0.32. The company’s fifty day moving average is $409.91 and its 200 day moving average is $423.26. The company has a debt-to-equity ratio of 4.45, a quick ratio of 2.49 and a current ratio of 2.54. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55.

Insider Transactions at Alnylam Pharmaceuticals

In other news, EVP Jeffrey V. Poulton sold 2,780 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $362.87, for a total transaction of $1,008,778.60. Following the sale, the executive vice president directly owned 57,465 shares in the company, valued at approximately $20,852,324.55. This represents a 4.61% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Yvonne Greenstreet sold 9,577 shares of the stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $362.86, for a total transaction of $3,475,110.22. Following the completion of the transaction, the chief executive officer directly owned 78,411 shares of the company’s stock, valued at approximately $28,452,215.46. The trade was a 10.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 56,955 shares of company stock worth $24,072,733. 1.50% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.